Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 48946010 approvals

BIOBIJOU Co., Ltd.

Official website

KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.

As of 2026-10-10, BIOBIJOU Co., Ltd. has 10 Korean MFDS device approvals on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2018 and listed on KOSDAQ in 2025, BIOBIJOU is a hyaluronic acid (HA)-based skin booster and filler company focused on aesthetics exports. Its products include the cross-linked HA skin booster CANDOLOV SERUM, the non-cross-linked ASCENART AQUA, and filler brands COLENA PREMIUM and CANDORLOV, alongside OEM products including the COLENA CE filler, the botulinum-toxin-based ELLEROX, and the CDL Cosmetics skincare brand. Its filler products use a patented dialysis device (registration no. 10-2662592) to resolve BDDE residue issues, its CANDOLOV SERUM applies a patented cross-linked HA composition (registration no. 10-2686600), it holds exclusive distribution rights for the exosome product ASCE+ in China, and CDL Cosmetics has entered the North American market via a D2C model.

Products & technology

  • CANDOLOV SERUMCross-linked HA skin booster
  • ASCENART AQUANon-cross-linked HA skin booster
  • SPEETIQUELSkin booster with Acetyl Hexapeptide-8
  • COLENA PREMIUMHA dermal filler
  • CANDORLOVHA dermal filler
  • COLENA CEDermal filler (OEM)
  • ELLEROXBotulinum toxin A wrinkle treatment (OEM)
  • CDL CosmeticsSkincare (cream, serum, mist, mask pack)
  • ASCE+Exosome product

Regulatory approvals

data.go.kr

10 Korean MFDS device approvals · 2021–2026

  • MFDSGraft/prosthesis, biomaterial2026-04-02
    Product approval · Class 4제허 26-253 호
  • MFDSGraft/prosthesis, biomaterial2025-11-07
    Product approval · Class 4제허 25-750 호
  • MFDSGraft/prosthesis, biomaterial2025-10-21
    Product approval · Class 4제허 25-708 호
  • MFDSGraft/prosthesis, biomaterial2025-09-11
    Product approval · Class 4제허 25-633 호
  • MFDSGraft/prosthesis, biomaterial2025-09-11
    Product approval · Class 4제허 25-631 호
  • MFDSGraft/prosthesis, biomaterial2025-02-25
    Product approval · Class 4제허 25-111 호
  • MFDSGraft/prosthesis, biomaterial2024-08-05
    Product approval · Class 4제허 24-525 호
  • MFDSGraft/prosthesis, biomaterialRevoked2024-05-14
    Product approval · Class 4제허 24-328 호
  • MFDSGraft/prosthesis, biomaterial2022-07-11
    Product approval · Class 4제허 22-441 호
  • MFDSGraft/prosthesis, biomaterial2021-03-15
    Product approval · Class 4제허 21-190 호

R&D and key agreements

Source: DART corporate disclosure

가교 히알루론산 조성물 기술 · 특허 등록 10-2686600 · Applied to CANDOLOV SERUM

가교제 투석 제거장치 기술 · 특허 등록 10-2662592 · Resolves BDDE residue issue in fillers

LNP(지질나노입자) 기술 적용 아세나르트 라인업 확장

Key disclosures

KRX KIND via OpenDART

Patents

KIPRIS · applicant-matched
Show 3 more patents

AI reads

MAA server logs · IP-verified
98
Times AI engines pulled BIOBIJOU Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

97
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

11
live 0
Last 7 days
75
live 1
Last 30 days
98
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot83
  • GoogleGoogleOther5
  • PerplexityPerplexityBot5
  • MicrosoftBingbot2
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for BIOBIJOU Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

BioPlus Co., Ltd2 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

DongBang Medical Co., Ltd.2 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

Chabiotech Co.,Ltd.2 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

DAE HWA PHARM CO., LTD2 shared

KOSDAQ-listed pharmaceutical company behind the world's first oral paclitaxel Liporaxel (DHP107) and the Amalian dermal filler.

JETEMA Co.,Ltd.2 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

PharmaResearch Co., Ltd.2 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

Humedix Co., Ltd.2 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

BNC KOREA, Inc.2 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

DongKookPharmaceuticalCo.,Ltd.2 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

CAREGEN CO.,LTD.2 shared

CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.

L&C BIO Co., Ltd1 shared

L&C BIO manufactures human tissue grafts across 11 tissue types, including the acellular dermal matrix MegaDerm, plus tissue-based medical devices.

T&R Biofab Co., Ltd1 shared

Founded in 2013 and KOSDAQ-listed in 2018, T&R Biofab commercializes 3D bioprinting systems, bioinks, and biodegradable scaffolds.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition